INDV
NASDAQIndivior Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings7
Price$35.98+0.22 (+0.63%)
01:30 PM07:45 PM
News · 26 weeks56+500%
2026-03-012026-08-23
Mix1890d
- SEC Filings9(50%)
- Insider5(28%)
- Earnings3(17%)
- Analyst1(6%)
Latest news
25 items- INSIDERChief Accounting Officer Anderson Woodrow D bought $54,420 worth of shares (1,500 units at $36.28), increasing direct ownership by 6% to 26,138 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Filed by)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Filed by)
- SECSEC Form 10-Q filed by Indivior Pharmaceuticals Inc.10-Q - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- SECSEC Form 425 filed by Indivior Pharmaceuticals Inc.425 - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
- SECSEC Form 8-K filed by Indivior Pharmaceuticals Inc.8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- PRIndivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance• Q2’26 Total Net Revenue of $343 Million, Up 14% YoY • Record Quarterly Total SUBLOCADE® Net Revenue of $253 Million in Q2'26, Up 21% YoY • Record Quarterly GAAP Net Income of $122 Million and Record Non-GAAP Net Income of $142 Million in Q2'26 • Record Quarterly Adjusted EBITDA of $186 Million in Q2'26, Up 111% YoY • Repurchased Approximately 4.7 Million Shares in Q2'26 for $175 Million RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance. "Exceptional operational execution in Phase II – Accelerate – of
- PRSupernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant ScaleCombines highly complementary businesses, with a diversified portfolio of CNS medicines totaling approximately $2.2 billion in combined annual revenuesEnhanced financial position and free cash flow generation enabling greater financial flexibility to pursue internal and external growth opportunitiesCombined company expected to benefit from immediate scale and $125 million of expected annual cost synergiesCombined entity to be named Supernus, Inc. and Jack Khattar to serve as President and Chief Executive Officer Companies to host joint conference call at 8:30 a.m. EDT today ROCKVILLE, Md. and RICHMOND, Va., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and
- PRIndivior to Report Second Quarter 2026 Financial Results and Host WebcastRICHMOND, Va., July 23, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company’s website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/yoi9z435 Participants may acce
- INSIDERChief Scientific Officer Heidbreder Christian sold $764,628 worth of shares (18,586 units at $41.14) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 209,337 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERChief Executive Officer Ciaffoni Joseph converted options into 1,266,903 shares and covered exercise/tax liability with 612,549 shares, increasing direct ownership by 481% to 790,330 units (SEC Form 4) to cover taxes4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- ANALYSTBarclays initiated coverage on Indivior with a new price targetBarclays initiated coverage of Indivior with a rating of Overweight and set a new price target of $46.00
- INSIDERChief Scientific Officer Heidbreder Christian sold $707,383 worth of shares (18,586 units at $38.06) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 227,923 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERChief Financial Officer Preblick Ryan sold $1,357,200 worth of shares (36,000 units at $37.70) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 284,751 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- PRNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare UtilizationCompared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly injectable buprenorphine had a 62% lower incidence of bacteremia and fewer inpatient, emergency, and outpatient visits than those receiving daily oral buprenorphine RICHMOND, Va., May 20, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc., (NASDAQ:INDV) today announced findings from two new real-world evidence studies showing that adherence to extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, is associated with lower relapse r
- SECIndivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
- INSIDERDirector Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Ninivaggi Daniel A was granted 6,518 shares, increasing direct ownership by 32% to 27,163 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
- INSIDERDirector Ryan Barbara was granted 6,518 shares, increasing direct ownership by 114% to 12,242 units (SEC Form 4)4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
INDV FAQ
5 questionsWhere does INDV stock trade?
Indivior Pharmaceuticals Inc. (INDV) is listed on NASDAQ.What sector and industry is INDV in?
Indivior Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about INDV?
Indivior Pharmaceuticals Inc. has had 7 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $4600.00 price target on 2026-06-18. Recent price targets range from $1600.00 to $4600.00.What companies are similar to INDV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare INDV side-by-side with any of them on Quantisnow.How can I track INDV on Quantisnow?
Quantisnow aggregates Indivior Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow INDV to receive live email and push alerts on every new disclosure.